Adalimumab: A Review in Chronic Plaque Psoriasis
Adalimumab: A Review in Chronic Plaque Psoriasis
复制标题
DOI：
10.1007/s40265-015-0503-x
复制
发表时间：
2015-12-01
期刊：
影响因子：
11.5
通讯作者：
McKeage, Kate
中科院分区：
文献类型：
--
作者：
Burness, Celeste B.;McKeage, Kate
阿达木单抗（Humira）是一种针对肿瘤坏死因子（TNF）的全人源单克隆抗体，用于皮下给药。它在治疗成人中至重度慢性斑块性银屑病方面已经很好地建立起来，最近在欧盟获得批准，用于治疗4岁以上儿童和青少年的重度慢性斑块性银屑病。在一项针对儿科患者的III期试验中，与接受甲氨蝶呤治疗16周后相比，每隔一周接受阿达木单抗0.8 mg/kg（至最大40mg）治疗的患者在牛皮癣面积和严重程度指数方面比基线改善>= 75%的比例显著更高。在成人中，精心设计的随机临床试验表明，阿达木单抗40mg有效地减轻了牛皮癣的体征和症状，改善了皮肤病特异性和健康相关生活质量的一般测量，这些益处在长期治疗期间持续存在。在儿童和成人慢性斑块型银屑病患者的临床试验中，与安慰剂或甲氨蝶呤相比，阿达木单抗通常耐受性良好。因此，阿达木单抗仍然是成人中重度慢性斑块型银屑病的重要治疗策略，并为4岁以上重度银屑病儿童和青少年提供了一种有希望的新的全身治疗选择。
Adalimumab (Humira (R)) is a fully human monoclonal antibody against tumour necrosis factor (TNF), formulated for subcutaneous administration. It is well established in the treatment of adults with moderate-to-severe chronic plaque psoriasis and has recently received approval in the EU for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age. In a phase III trial in paediatric patients, a significantly greater proportion of patients receiving adalimumab 0.8 mg/kg (to a maximum of 40 mg) every other week (eow) achieved a >= 75% improvement from baseline in Psoriasis Area and Severity Index than those receiving methotrexate after 16 weeks of treatment. In adults, well-designed randomized clinical trials demonstrated that adalimumab 40 mg eow effectively reduced the signs and symptoms of psoriasis and improved dermatology-specific and general measures of health-related quality of life, with these benefits sustained during long-term treatment. Adalimumab was generally well tolerated, compared with placebo or methotrexate, during clinical trials in paediatric and adult patients with chronic plaque psoriasis. Thus, adalimumab remains an important treatment strategy in adults with moderate-to-severe chronic plaque psoriasis and provides a promising new systemic treatment option for children and adolescents from 4 years of age with severe psoriasis.